Towards the development of next-generation lung cancer immunotherapy

Introduction

Therapies for lung cancer have undergone dramatic changes, with immune checkpoint inhibitors (ICIs) playing key roles. The antitumor immune response that acts locally in the area of the tumor is primed in the regional lymph nodes. However, it is also recognized that there are mechanisms that can maintain the activity of antitumor cells in the locality of the cancer. Examination of the immune tumor microenvironment (TME) has critical prognostic value and can supplement histopathological and molecular biomarkers for the evaluation of patient responses to treatment. The TME refers to the environment surrounding tumor cells; it is dynamic and is constantly subject to various influences from other normal cells and tissues. Humans are inherently equipped with tumor immunity to eliminate tumors; however, in the TME, tumor immunity can be suppressed by various mechanisms. In addition to tumor cells themselves suppressing tumor immunity, the important role of non-tumor cells in the TME is gradually becoming clear, and the effectiveness of ICIs is greatly influenced by the TME. Furthermore, immune responses are multifaceted, with innate and adaptive immunity. Adaptive immunity comprises cellular and humoral immunity. It was reported that CD8+ T cells and M1 macrophages are correlated with a favorable prognosis (1). High levels of CD3+ T cell infiltration in ovarian cancer correlated with favorable progression-free survival (PFS) and overall survival outcomes (2). In colorectal cancer, cases in which there were many TH1 differentiated memory T cells [positive for interferon (IFN) γ expression] and cytotoxic CD8+ T cells (positive for granzyme and granulysin expression) infiltrating into the tumor at the time of diagnosis had a good prognosis (3). Major histocompatibility complex (MHC) I expression on cancer cells was positively correlated with PFS and overall survival in breast cancer cases (4,5). Duhen et al. reported that CD103+ CD39+ CD8 T cells kill cancer cells in an MHC class I-restricted manner in head and neck cancer, and that a high proportion of this population of tumor-infiltrating lymphocytes (TILs) was a good prognostic factor (6). It was reported that in most cancers, including non-small cell lung cancer (NSCLC), pancreatic cancer, breast cancer, renal cell carcinoma, hepatocellular carcinoma, and melanoma, cases with a high infiltration of forkhead box protein P3 (FOXP3)⁺ CD4⁺ CD25⁺ lymphocytes in the tumor have a poor prognosis (1). Most macrophages present in tumors are M2 type, which promotes the progression of cancer cells. Infiltration of M2 type macrophages into tumors was reported to be a poor prognostic factor in breast cancer, bladder cancer, ovarian cancer, gastric cancer, prostate cancer, renal cell carcinoma, and melanoma (1). In patients with NSCLC, cancer growth is associated with increased expression of T cell exhaustion markers on tumor-infiltrating CD8+ T cells, many of which are immune checkpoint proteins that control T cell proliferation [e.g., programmed cell death-1 (PD-1), T cell immunoglobulin domain and mucin domain protein 3 (TIM-3), cytotoxic T-lymphocyte associated antigen-4 (CTLA-4), lymphocyte-activation gene 3 (LAG-3), and B and T lymphocyte attenuator (BTLA)] (7). LAG-3 (CD223) is an immune inhibitory molecule expressed on natural killer (NK) cells, activated T cells, and B cells, and exerts its inhibitory effect by binding to MHC class II. Similar to Treg cells, myeloid-derived suppressor cells (MDSCs) express CD39 and CD73 ectonucleotidases and convert adenosine triphosphate (ATP) to adenosine, which is considered an important mediator of immune suppression in the TME (8). MDSCs expressing CD39 and CD73 are present in the TME of NSCLC patients and are positively correlated with cancer progression, but these cells are significantly reduced by chemotherapy (9). Vascular endothelial growth factor (VEGF) proteins can inhibit the maturation, differentiation, and antigen presentation of professional antigen-presenting cells (APCs), dendritic cells (DCs), NK, and T cells, and enhance the suppressive effects of regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and MDSCs (10) (Table 1).

In current cancer treatments, ICIs have demonstrated excellent efficacy; however, in some cases, they are ineffective. CITYSCAPE was the first phase II randomized controlled trial to evaluate the efficacy and safety of anti-TIGIT and anti-PD-1/PD-L1 combination therapy. The combination arm showed a significant improvement in overall survival in patients with PD-L1 TPS ≥50% [hazard ratio (HR) 0.23, 95% confidence interval (CI): 0.10–0.53], but not in the overall population (HR 0.69, 95% CI: 0.44–1.07) (11). On the other hand, various adverse events associated with ICIs are also known. Atcheley et al. analyzed ICI-associated pneumonitis in 315 patients with lung cancer treated with nivolumab (76.5%) or pembrolizumab (22%). The incidence of ICI-associated pneumonitis was 9.5%. The presence of fibrosis on pretreatment chest CT scan [adjusted OR (aOR), 6.61; 95% CI: 2.48–17.7], degree of obstructive pulmonary disease (aOR, 2.79; 95% CI: 1.07–7.29), and treatment with pembrolizumab (aOR, 2.57; 95% CI: 1.08–6.11) were independent factors for the development of ICI-associated pneumonitis (12). There are also populations in which ICIs are less effective. Ricciuti et al. performed comprehensive genomic profiling and immunophenotypic characterization of samples from 82 NSCLC patients and pre- and post-ICI biopsy samples and compared the results with control patients who received non-ICI interventional therapy. In 27.8% of the ICI-treated group, putative resistance mutations were detected, including acquired loss-of-function mutations in STK11, b-2 microglobulin (B2M), APC, MTOR, KEAP1, and JAK1/2. These acquired changes were not observed in the control group (13). To achieve higher therapeutic efficacy, the development of next-generation lung cancer immunotherapies is essential. However, the effector cells involved in cancer immune responses are highly diverse and many cells and mediator molecules promote or suppress effector cells (Figure 1, Table 2), which complicates our understanding. In this review, we considered each factor thought to be related to next-generation lung cancer immunotherapy.

Figure 1 Immune cells involved in antitumor immunity. There are various immune cells involved in anti-tumor immunity. There are interactions, and the functions of individual immune cells can vary, making understanding difficult. Nevertheless, it is necessary to develop next-generation cancer immunotherapy by understanding the basic characteristics of each immune cell. ADCC, antibody dependent cellular cytotoxicity; CDC, complement dependent cytotoxicity; MDSC, myeloid-derived suppressor cells; CAF, cancer-associated fibroblast.

Tertiary lymphoid structures (TLS)

A cycle exists in which activated T cells gather in the interstitium, particularly in the TLS, where immune cells interact to maintain their effector functions. TLS, which represent organized secondary lymphoid organ-like cellular aggregates occur locally (14) and may regulate antitumor immune responses through a mechanism distinct from that of the normal cancer immune cycle. At tumor sites, TLS enable the localized presentation of cancer antigens by DCs and the production of effector T cells and antibody-producing plasma cells, which is associated with a favorable prognosis in a variety of cancer types (15). Within tumors, B cells were not found alone but tended to co-localize with CD4 and CD8 TILs, and cases in which B cells and CD8 T cells were found simultaneously within tumors tended to have a better prognosis than cases in which only CD8 T cells were found (16). TLS are ectopic lymphoid organs that develops in nonlymphoid tissues at sites of chronic inflammation, including tumors. A T-cell zone containing mature DCs is formed around CD20⁺ B cells, plasma cells, follicular helper T cells, and follicular DCs.

In lung cancer, colorectal cancer, pancreatic cancer, oral squamous cell carcinoma, and invasive breast cancer, the presence of TLS have been associated with increased overall and recurrence-free survival (14).

Tumor-infiltrating B cells within the TLS are associated with the therapeutic effects of ICI (17-19).

TILs

TILs are lymphocytes that infiltrate tumors and include tumor-reactive and antigen-specific lymphocytes. A treatment method in which tumor-reactive T cells in TILs were expanded and infused was attempted. It has been suggested that TILs also contain many cell groups that negatively regulate antitumor immune responses, including regulatory T cells. In addition to lymphocytes, regulatory cell groups in the MDSCs, TAMs, cancer-associated fibroblasts (CAFs), and mesenchymal stem cells (MSCs). Depending on the degree of T-cell infiltration, a tumor can be classified into three types: immune desert, immune-excluded, and inflamed. In the immune desert, immune cells in the tumor are clearly depleted, which may be related to immune cell repulsion or migration (possibly due to a lack of attractive chemokines, hypoxia, and lack of nutrients). In immune exclusion, the presence of inhibitory stroma and extracellular matrix (ECM) may prevent T cells from effectively migrating and coming into direct contact with cancer cells, thereby allowing cancer cells to survive. Peritumoral or intratumoral inflammatory cells that promote immune responses may activate TILs and increase their function and proliferation (20).

In TILS, PD-1⁺ CD8⁺ T cells are associated with a good prognosis, while PD-1⁺ Tregs are associated with a poor prognosis, and the balance of the ratio of PD-1 expression between them could be a biomarker (21).

Tumor mutation burden (TMB)

The greater the TMB, the more cancer-specific CD8+ T cells will be present and infiltrate the tumor, which is thought to result in a hot tumor. When cancer cells are exposed to IFN-γ secreted by CD8⁺ T cells that have infiltrated into the tumor, they increase the expression of programmed cell death-ligand 1 (PD-L1), thereby suppressing the antitumor effect of CD8+ T cells via the inhibitory receptor PD-1 expressed on activated CD8⁺ T cells. ICIs are thought to be effective in treating such hot tumors. IFN-γ is a multifunctional cytokine with antiviral, antitumor, and immunomodulatory functions, and plays an important role in controlling both innate and adaptive immunity (22). IFN-γ promotes immune responses and induces the elimination of pathogens. It also prevents overactivation of the immune system and tissue damage, although the regulatory mechanisms remain unclear (23,24). In the tumor TME, IFN-γ consistently controls both pro-tumor and anti-tumor immunity. IFN-γ acts as a cytotoxic cytokine together with granzyme B and perforin to induce apoptosis of tumor cells (25,26), while it promotes the synthesis of ICIs and indoleamine-2,3-dioxygenase (IDO), inducing immunosuppression (27-29).

In some cancers, reduced mismatch repair (MMR) has been observed. In sporadic MMR-deficient (dMMR) solid tumors, the cause is often acquired hypermethylation of the promoter region of the MLH1 gene or reduced expression owing to mutations in the MMR genes (30). The occurrence of a congenital pathogenic variant of the MLH1, MSH2, MSH6, or PMS2 genes, or a deletion of the epithelial cell adhesion molecule (EPCAM) gene (31-33) adjacent to the upstream region of the MSH2 gene in one allele, it is called Lynch syndrome, and dMMR tumors are known as Lynch-associated tumors.

CD8⁺ T cells

CD8⁺ T cells recognize antigen peptides presented on MHC class I by their specific T cell receptor (TCR) and exert their effector functions by releasing perforin, granzymes, etc. However, CD8⁺ T cells become exhausted in cancer and chronic infections, and their cytotoxic activity and proliferative ability decrease. In some cases, CD8⁺ T cells infiltrate the tumor, whereas in others, there is little infiltration. If tumor-specific CD8⁺ T cells are present, they become cytotoxic T lymphocytes (CTLs), infiltrate the tumor, and damage cancer cells. This may make immunotherapy more effective and improve prognosis. It has been reported that CD103⁺ CD8⁺ T cells infiltrating the tumor can be used as biomarkers for ICI effectiveness (34). CD103 is a ligand for the adhesion molecule E-cadherin. E-cadherin is expressed by epithelial cells, forming part of the adherent junctions between epithelial cells. When T cells infiltrate regions with epithelial cells, including cancer cells, they begin to express CD103 (6). Therefore, it has been reported that CD103⁺ T cells have previously encountered epithelial cells, including cancer cells, and are almost identical to tumor-specific T cells.

Using resected specimens from patients with lung cancer, CD103⁺ lymphocytes were confirmed by immunostaining in the local tumor area and associated lymph nodes. It has been reported that prognosis after lung cancer resection is better when there was a high level of CD103⁺ lymphocyte infiltration.

We analyzed the immunological molecular expression in local and regional lymph node microenvironments using resection sections from 50 cases of lung squamous cell carcinoma. The expression of MHC class I and PD-L1 molecules in the tumor did not affect the prognosis; however, CD103⁺ lymphocyte infiltration was a good prognostic factor (35). Furthermore, an analysis of 21 cases of NSCLC suggested that an increase in CD103⁺ CD39⁺ CD8⁺ T cells in the peripheral blood after ICI administration was a favorable prognostic factor, and that an increase in CD103⁺ CD39⁺ CD8⁺ T cells may enhance the cancer immune response (36). PD-1⁺ and CD8⁺ T cells in TILs are associated with a good prognosis, whereas PD-1⁺ Tregs in TILs are associated with a poor prognosis, and the balance of their PD-1 expression ratios can serve as a biomarker (21). In addition, we induced mutant p53-specific CTL clones from lymphocytes of the regional lymph nodes of patients with lung cancer, and demonstrated by TCR analysis [clonotypic polymerase chain reaction (PCR) method] that these CTL clones were present in the tumor locale and were involved in the cancer immune response (37). We also demonstrated that isolating tumor-specific TCR and transferring genes into γδ T cells, in a severe combined immunodeficiency (SCID) mouse model implanted with a human lung cancer cell line, resulted in tumor regression (38). As reviewed in another section, TCR-transduced cell therapy has been applied clinically and is attracting attention as next-generation immunotherapy.

CD4⁺ T cells

CD4⁺ T cells recognize antigen peptides presented on MHC class II molecules via their specific TCRs and are activated. They function as effector cells and participate in B-cell differentiation and proliferation. Kagamu et al. reported that patients whose peripheral blood CD62L^low CD4⁺ T-cell populations decreased after ICI administration had a weakened therapeutic response, whereas those who survived for a long time maintained a high percentage of CD62L^low CD4⁺ T-cells (39). Monitoring the immune status of CD4+ T-cells in the peripheral blood of patients receiving ICIs may predict treatment efficacy.

CD4⁺ T helper (Th) lymphocytes act as key regulators of inflammation specific to the encountered threat, with a large (and expanding) list of Th subsets defined to date, including Th1, Th2, Th17, Th9, and Th22. Th1 responses are characterized by the production of IFN-γ, tumor necrosis factor (TNF)-α, and interleukin (IL)-2 by T cells and are thought to be the essential subset for tumor rejection. IFN-γ generated from Th1 responses may synergize with IL-17 produced by Th17 cells to promote the secretion of the chemokines CXCL9 and CXCL10 that can recruit CTLs to the TME to target tumor cells (40).

In addition to a chronic inflammatory TME, prolonged exposure to tumor antigens induces Th1 and other T cells that lack the typical polyfunctional phenotype (i.e., the ability to secrete large amounts of several cytokines) to express inhibitory receptors, such as PD-L1, LAG-3, and TIM-3 (41). The antitumor efficiency of exhausted T cells is severely limited. Interestingly, a positive correlation was found between the number of CD8⁺ TILs and a favorable clinical prognosis (41,42).

B cells

B cells play a central role in humoral immunity. They express the membrane-type globulin BCR on their cell surface, take up antigens into the cell, and present them to CD4⁺ T cells. Through the interactions between B and T cells, B cells differentiate into plasma cells and produce antibodies.

As the TLS mature, lymphoid follicles are often observed and are thought to contribute to the maintenance of the effector function of immune cells by interacting with T cells and B cells. It is also known that cases in which tumor-infiltrating B lymphocytes (TIBs), as well as CD8⁺ T cells are present in the TLS, the tumor tend to have a better prognosis than cases in which only CD8⁺ T cells are present (43). TIBs directly support antitumor immunity. Microdissection of melanoma TLS revealed clonal proliferation, isotype switching, and somatic mutations in BCR-rare cells, suggesting the induction of antigen-specific antibody responses (44). TIBs may also be involved in the maintenance of TLS by producing CXCL13 and lymphotoxin (45). It was reported that a network of CXCL13⁺ stromal cells within primary follicles promotes B cell migration and follicle formation (46). The CXCL13-producing CD8-LAYN subset appears primarily in tumor tissues and may promote the recruitment and organization of CD20⁺ B cells within TLS (47). TLSs are associated with increased overall survival and PFS in patients with lung cancer, colon cancer, pancreatic cancer, oral squamous cell carcinoma, and invasive breast cancer (14). TIBs in TLS are reportedly related to the therapeutic effects of ICIs (17-19). Activated T cells gather in the interstitium; in particular, in the TLS, immune cells interact with each other, creating a cycle that maintains the effector function of immune cells.

Regulatory T cells

Treg cells suppress immune responses, including the excessive immune responses that cause autoimmune diseases, inflammatory diseases, and allergies. Conversely, when Treg cells work excessively, they suppress immune responses against pathogens such as cancer cells and promote cancer growth.

In 2003, Sakaguchi et al. reported that the transcription Foxp3, identified as the causative gene of the human autoimmune disease immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome, is selectively expressed in Treg cells and acts as a “master transcription factor” that controls their development, differentiation, and immunosuppressive functions (48). Since this discovery, extensive research on the mechanisms of Treg cell differentiation and function has been conducted, revealing that Foxp3 forms complexes with over 300 other transcription factors in Treg cells, binds to thousands of locations in the genome, and controls gene expression in Treg cells. Tregs maintain systemic immune homeostasis by regulating peripheral tolerance and attenuating autoimmune diseases (49) via various immunosuppressive mechanisms (50). Treg depletion experiments in mice found that this population potently suppresses antitumor effector T cell responses and blocks tumor elimination by endogenous tumor-specific effector T cells (51,52). Wing et al. reported that CTLA-4 on Tregs reduced the expression of CD80/86, a costimulatory molecule on DCs, thereby suppressing T-cell activation (53). Anti-CTLA-4 antibodies suppress the function of CTLA-4 and can, therefore, control Treg function. Infiltrating Tregs can be classified into two types based on their biological properties: natural regulatory T cells (nTregs) and inducible regulatory T cells (iTregs). nTregs naturally occur in the thymus and their main functions are to maintain normal immune tolerance and control inflammatory responses, and their suppressive effect is achieved through cell-cell contact. iTregs originate from peripheral naive T cells induced by tumor antigens, cytokines such as TGF-β, and other TME signals (54). Cancer stimulates newly generated iTreg cells and recruits nTreg cells to tumor sites, providing a favorable environment for the induction and maintenance of Treg cell characteristics. FOXP3 is ubiquitously expressed in both nTregs and iTregs (55-57). Th17 cells are also a source of tumor-induced FOXP3⁺ T cells. Tumor-induced Th17 cells gradually differentiate into inhibitory IL-17A⁺FOXP3⁺ and ex Th17FOXP3⁺ Tregs during tumorigenesis (58).

The TME is a nutrient-poor, lactate-rich, hypoxic environment that supports the bioenergetic needs of cancer cells that depend on aerobic glycolysis, fatty acid synthesis, and glutaminolysis (59). FOXP3 expression reprograms Treg metabolism to function in a low-glucose, high-lactate environment, making Treg cells more suitable for the TME (60).

NK cells

NK cells kill cancer cells without sensitization. NK cells eliminate cancer cells through effector functions mediated by cytotoxic granule contents such as perforin and granzymes, death ligands such as Fas-ligand and TNF-related apoptosis-inducing ligand (TRAIL), and cytokine production such as IFN and TNF-α (61). MHC class I chain-related protein A and B (MICA/B) are ligands that activate NK cells through the activating receptor natural killer group 2 member D (NKG2D) (62-65), and downregulation of MICA/B expression induces immune evasion (66,67). MHC class I molecules act on inhibitory receptors of NK cells, such as killer cell immunoglobulin-like receptors (KIR), and suppress the effector functions of NK cells (68). Currently, attempts are being made to apply chimeric antigen receptor-T (CAR-T) cells and TCR-transduced T cells in immunotherapy by introducing CAR genes or T-cell receptors into NK cells (69).

Natural killer T (NKT) cells

NKT cells have an invariant TCR, Vα14Jα18 in mice and Vα24Jα18 in humans. The invariant TCR recognizes glycolipids such as α-galactosylceramide (α-GalCer) presented on the MHC class I-like molecule CD1d as a ligand (70). NKT cells are activated by stimulation with α-GalCer, and express cytokines such as IFN-γ and TNF, as well as cytotoxic factors such as perforin, granzymes, FAS ligand, and TRAIL, which can directly damage cancer cells. NKT cells are also activated by DCs (71), and it is known that activated NKT cells subsequently leads to DC maturation and activation, thereby inducing effective adaptive immunity (72,73).

γδ T cells

γδ T cells express various receptors (74). 4-Hydroxy-3-dimethyl-allyl-pyrophosphate produced by bacteria, exogenous antigens derived from viruses, and endogenous phosphate antigens isopentenylpyrophosphate and triphosphoric acid 1-adenosin-5-yl ester 3-(3-methylbut-3-enyl) ester are recognized by γδ TCRs. MICA/B, which is expressed on the cell surface by stress, is recognized by NKG2D receptors. γδ T cell therapy has been administered to patients with treatment-resistant lung cancer, and 6 of 14 patients showed stable disease using RECIST, with a median PFS of 126 days and a median survival time of 586 days. IFN-γ was detected in the blood of seven patients during treatment, and four of these showed stable disease. Although no statistically significant difference was detected, it is thought that an increase in IFN-γ in the blood may affect prognosis (75,76).

It was also reported that dysregulation of the local microbiota stimulated tissue-resident γδ T cells to produce IL-17 and other proinflammatory mediators, promoting neutrophil proliferation and tumor cell growth. IL-17 first gained prominence as a cytokine that drives autoimmune and inflammatory diseases. New studies have revealed that IL-17 plays a key role in maintaining mucosal immunity and barrier integrity (77,78). These two fundamental physiological functions may not only establish host defense but also promote tumorigenesis and cancer progression in pathological situations. These pathophysiological functions rely on IL-17’s ability to induce inflammatory mediators, its mitogenic effects in tissue progenitor cells, and its ability to reprogram cellular metabolism (79). This may further enhance inflammation and microbiota dysbiosis, establishing a vicious cycle that exacerbates tumor growth (80).

TAMs

Macrophages release inflammatory mediators and secrete angiogenic factors. In malignant tumors, macrophages are divided into two categories: M1 macrophages that are involved in the Th1 cell response to pathogens and promote antitumor immunity, and M2 macrophages that are involved in the Th2 cell response and suppress antitumor immunity (81,82). TAMs are primarily composed of M2 macrophages that transform the TME into an immunosuppressive and tumor-progressing state, leading to a poor prognosis (82).

Microparticles released from irradiated tumor cells (RT-MPs) induce a wide range of antitumor effects and immunogenic cell death primarily via iron-dependent pathways. RT-MPs induce DNA double-strand breaks in tumor cells and significantly upregulate MHC-I expression on the membranes of non-irradiated cells, enhancing the recognition and killing of these cells by T cells (83). It was reported that RT-MPs can convert M2-TAMs in the pleural effusion microenvironment into M1-TAMs via the JAK-STAT and MAPK pathways (84).

DCs

When foreign substances enter the body, DCs phagocytose, process, and present fragmented antigen peptides to the MHC. Naïve T cells recognize and are activated by antigen peptides. DCs are essential for initiating immune responses. Tumors DCs infiltrating the TLS induce a Th1-type immune shift and improve lung cancer prognosis (85). Tissue-resident DCs can be divided into two major subsets based on transcription products and function. CD1c⁺ DCs are thought to be generated from monocytes during the invasion of tumor sites, whereas CD141⁺ DCs appear to be generated from DC-restricted precursors (86,87). The expression of lymphotoxin beta transcripts by CD141⁺ DC subsets in lung tumor tissues may reflect the contribution of CD141⁺ DCs to TLS formation, possibly due to HEV-mediated lymphocyte recruitment (88). The expansion of intratumoral CD141⁺ DCs may be an important strategy for inducing potent antitumor immunity. In a multicenter, single-arm, phase I/II study, a combination therapy consisting of anti-PD-L1 blockade and Wilms’ tumor antigen 1-DC vaccination was administered to patients with epithelioid malignant pleural mesothelioma (89). It was also reported that the use of a DC vaccine as postoperative adjuvant therapy in patients with pancreatic cancer resulted in good recurrence-free survival rates (90).

MDSCs

MDSCs, a heterogeneous group of immature myeloid cells, have immunosuppressive properties that increase in the blood and lymphatic tissues of patients with both cancer and infectious diseases (91). MDSCs are classified into polymorphonuclear MDSCs (CD11b⁺CD14⁻CD15⁺ or CD11b⁺CD14⁻CD66b⁺), which resemble neutrophils, and monocyte MDSCs (CD11b⁺CD14⁺CD15HLA-DR^low/−), which resemble monocytes. In patients with cancer, MDSCs suppress the anticancer immune reactions of CD4⁺ T cells, CD8⁺ T cells, and NK cells, inducing tumor progression. Strategies targeting MDSCs in cancer immunotherapy include promotion of MDSC differentiation (92), inhibition of their suppressive function (93,94), and elimination of MDSCs (95). Pan et al. reported that MDSCs induce Tregs via CD40-CD40L (96). The blockade of CD40-CD40L may suppress the functions of MDSCs and Tregs and may have therapeutic effects.

Neutrophils

Neutrophils can also be recruited and infiltrate the TME as tumor-associated neutrophils (TANs) (97,98). TANs may promote tumor development by generating reactive oxygen species (99), releasing neutrophil elastase to accelerate tumor growth (100), secreting matrix metalloproteinase-9 to induce angiogenesis (101), and forming neutrophil extracellular traps to promote tumor metastasis (102). Neutrophil abundance has prognostic significance in NSCLC. Patients with a high neutrophil-to-lymphocyte ratio had reduced PFS and overall survival (103,104). Patients with early stage NSCLC and increased CD66b-positive neutrophil infiltration were more likely to experience recurrence after surgery (105). Approaches that inhibit cytokines and chemokines that promote neutrophil infiltration, or mediators involved in neutrophil function, may be necessary.

CAFs

As central components of the TME in primary and metastatic tumors, CAFs profoundly influence the behavior of cancer cells and are involved in cancer progression through extensive interactions with cancer cells and other stromal cells. CAFs exert immunosuppressive effects by acting as a physical barrier to T cells and releasing immunosuppressive chemical mediators. CAFs secrete matrix metalloproteinases (MMPs), including MMP2, MMP3, and MMP9, or activate YES-associated proteins to promote ECM degradation and remodeling, epithelial-mesenchymal transition, and cancer stem-cell stemness (106-110). In the TME, the hypoxic niche communicates bidirectionally with the mechanical microenvironment mediated by CAFs. Cords et al. found that CAFs are a heterogeneous group with both poor and good prognostic phenotypes. Spatially resolved single-cell imaging mass cytometry (IMC) of CAFs was analyzed in a cohort of 1,070 patients with NSCLC. They identified four prognostic patient groups based on 11 CAF phenotypes with different spatial distributions and found CAFs to be independent prognostic factors. The presence of tumor-like CAFs was an independent poor prognostic factor, whereas inflammatory CAFs and IFN-response CAFs were favorable prognostic factors. High density of matrix CAFs correlated with low immune infiltration and was a poor prognostic factor. CAF phenotypic and spatial features associated with patient outcome in NSCLC were identified. Therefore, it may be necessary to develop treatments that consider the tailored phenotype (111).

Chimeric antigen receptor-T cells

CAR-T and TCR-transduced effector cells are genetically engineered synthetic biological approaches that target tumor-specific antigens and exert remarkable therapeutic effects (112,113). The components of CAR-T cells have been continuously improved and consist of a single-chain antibody (single-chain antibody variable fragment, scFV), a flexible connecting chain (hinge), a transmembrane domain and the signaling domains of the costimulatory molecule CD28, 4-1BB or OX-40 and stimulatory molecule CD3ζ and FcRγchain (Figure 2). CAR-T cell immunotherapy has demonstrated remission rates of 80–100% in hematological malignancies, with CD19-targeted CAR-T cells approved for the treatment of blood cancers. The recent success of CAR-T therapy has transformed the cancer treatment landscape and spurred research efforts to apply these therapeutic effects to solid tumors, such as lung cancer (114). Novel approaches are currently being investigated to test the applicability of CAR T-cell immunotherapy in lung cancer. CXCR4 is upregulated in lung cancer tissues and cell lines (115), and has been validated as a target for NSCLC treatment (116). The MAGE-A1 antigen was selected by analyzing the cancer/testis antigen database, and MAGE-A1-specific CAR-T cell immunotherapy against lung adenocarcinoma has shown to be effective and safe (117).

Figure 2 Chimeric antigen receptor-T cells (CAR-T cells). The components of CAR-T cells consist of a single-chain antibody (single-chain antibody variable fragment, scFV), a flexible connecting chain (hinge), a transmembrane domain and the signaling domains of the costimulatory molecule CD28, 4-1BB or OX-40 and stimulatory molecule CD3ζ and FcRγchain.

Disialoganglioside (GD2) is highly expressed in SCLC and is a potential target for immunotherapy. As a novel approach to combat SCLC, iPSC-derived rejuvenated GD2-CART (GD2-CARrejT) has been developed. Compared with conventional GD2-CART, GD2-CARrejT with reduced expression of TIGIT and PD-1 exhibits potent cytotoxicity against SCLC and may be a promising treatment for SCLC (118).

Moles et al. reported that countering CAR downmodulation via CXCR4 co-expression in CAR-NK cell therapy may improve CAR-T effector function, an issue that has not been addressed in NK cells. Longer surface residence time likely delays endocytosis and lysosomal degradation (119). This may be due to (I) recruitment of P-ZAP-70 to synapses via CXCR4, (II) stabilization of synapses and CAR surface deposition, and (III) enhanced antigen-dependent CAR activation by hijacking or conspiring signaling nodes. The homeostatic chemokine receptor CXCR4 is thought to function as a coreceptor during the formation of CAR-mediated immunological synapses, which has been reported to be important in NK cells with low endogenous CXCR4 expression (120).

Mao et al. reported that MAGE-A1 is a promising target for lung adenocarcinoma and that the innovative MAGE-A1-CAR-T cell (mCART) exerts remarkable antitumor activity against MAGE-A1-positive lung adenocarcinoma, which is expected to become a new strategy for lung adenocarcinoma immunotherapy (117).

TCR-transduced effector cells

TCR-transduced effector cell therapy is a promising treatment strategy that induces strong cellular immune responses against lung cancer. However, it has limitations in that it can only be administered to patients with matched cancer antigen expression and HLA types. HLA0802-restricted KRAS mutation-specific TCR-injected autologous T-cell therapy resulted in 72% tumor regression in patients with KRAS mutation-positive pancreatic cancer. Furthermore, TCR-injected autologous T cells were detected in the peripheral blood more than six months after administration (121). Robbins et al. reported that NY-ESO-1-specific TCR-transduced T cells were administered to patients with synovial cell sarcoma and melanoma, and clinical responses were observed in four of six patients with synovial cell sarcoma and five of 11 patients with melanoma (122).

Conclusions

The widespread use of ICIs has caused a paradigm shift in lung cancer treatment, which continues to evolve. ICIs have fewer side effects than traditional chemotherapeutic drugs, improve overall survival rates, and play a central role in lung cancer chemotherapy. Currently, patients with lung cancer have several treatment options, ranging from single-agent immunotherapy to quadruple therapy, which combines immunotherapy with chemotherapy and anti-VEGF drugs. Elucidating the mechanism of resistance to ICIs is important for the development of next-generation immunotherapy; however, as reviewed in this article, the interactions between cells and molecules with the immune system and the immunological environment of the tumor are intricately related, making clarification of resistance mechanisms difficult. Perhaps, we are entering an era in which treatment plans will be individually tailored to each patient’s tumor immunological microenvironment and molecular expression.

Cell therapy has the potential to become a powerful next-generation therapy. With the development of molecular biology techniques, it is becoming possible to obtain ideal immunotherapeutic effects by transferring receptors with higher tumor specificity and affinity to more powerful effector cells. To develop promising treatments for effective lung cancer in the future, it is necessary to continue research to deepen our understanding of lung cancer and the surrounding immune system.

Acknowledgments

None.

Footnote

Peer Review File: Available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2024-1097/prf

Funding: The study received grant support from JSPS KAKENHI (22K09013, to Y.I.).

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2024-1097/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Fridman WH, Zitvogel L, Sautès-Fridman C, et al. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol 2017;14:717-34. [Crossref] [PubMed]
2. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13. [Crossref] [PubMed]
3. Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95. [Crossref] [PubMed]
4. Stoll G, Enot D, Mlecnik B, et al. Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. Oncoimmunology 2014;3:e27884. [Crossref] [PubMed]
5. Stoll G, Bindea G, Mlecnik B, et al. Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget 2015;6:11894-909. [Crossref] [PubMed]
6. Duhen T, Duhen R, Montler R, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 2018;9:2724. [Crossref] [PubMed]
7. Thommen DS, Schreiner J, Müller P, et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol Res 2015;3:1344-55. [Crossref] [PubMed]
8. Allard B, Longhi MS, Robson SC, et al. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev 2017;276:121-44. [Crossref] [PubMed]
9. Li J, Wang L, Chen X, et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology 2017;6:e1320011. [Crossref] [PubMed]
10. Ren S, Xiong X, You H, et al. The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer. Front Immunol 2021;12:689132. [Crossref] [PubMed]
11. Cho BC, Abreu DR, Hussein M, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 2022;23:781-92. [Crossref] [PubMed]
12. Atcheley WT, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer. Chest 2021;160:731-42. [Crossref] [PubMed]
13. Ricciuti B, Lamberti G, Puchala SR, et al. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non-Small-Cell Lung Cancer. J Clin Oncol 2024;42:1311-21. [Crossref] [PubMed]
14. Sautès-Fridman C, Petitprez F, Calderaro J, et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer 2019;19:307-25. [Crossref] [PubMed]
15. Pérez-Romero K, Rodríguez RM, Amedei A, et al. Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy. Int J Mol Sci 2020;21:5521. [Crossref] [PubMed]
16. Dieu-Nosjean MC, Goc J, Giraldo NA, et al. Tertiary lymphoid structures in cancer and beyond. Trends Immunol 2014;35:571-80. [Crossref] [PubMed]
17. Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577:556-60. [Crossref] [PubMed]
18. Helmink BA, Reddy SM, Gao J, et al. B cells and tertial lymphoid structures promote immunotherapy response. Nature 2020;577:549-55. [Crossref] [PubMed]
19. Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 2020;577:561-5. [Crossref] [PubMed]
20. Mellman I, Chen DS, Powles T, et al. The cancer-immunity cycle: Indication, genotype, and immunotype. Immunity 2023;56:2188-205. [Crossref] [PubMed]
21. Kumagai S, Togashi Y, Kamada T, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 2020;21:1346-58. [Crossref] [PubMed]
22. Mendoza JL, Escalante NK, Jude KM, et al. Structure of the IFNg receptor complex guides design biased agonists. Nature 2019;567:56-60. [Crossref] [PubMed]
23. Zhang J. Yin and yang interplay of IFN-gamma in inflammation and autoimmune disease. J Clin Invest 2007;117:871-3. [Crossref] [PubMed]
24. Ivashkiv LB. IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol 2018;18:545-58. [Crossref] [PubMed]
25. Tau GZ, Cowan SN, Weiburg J, et al. Regulation of IFN-g signaling is essential for the cytotoxic activity of CD8+ T cells. J Immunol 2001;167:5574-82. [Crossref] [PubMed]
26. Maimela NR, Liu S, Zhang Y. Fates of CD8+ T cells in Tumor Microenvironment. Comput Struct Biotechnol J 2019;17:1-13. [Crossref] [PubMed]
27. Mojic M, Takeda K, Hayakawa Y. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. Int J Mol Sci 2017;19:89. [Crossref] [PubMed]
28. Angelova M, Charoentong P, Hackl H, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol 2015;16:64. [Crossref] [PubMed]
29. Zaidi MR, Davis S, Noonan FP, et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature 2011;469:548-53. [Crossref] [PubMed]
30. McGivern A, Wynter CV, Whitehall VL, et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004;3:101-7. [Crossref] [PubMed]
31. Kuiper RP, Vissers LE, Venkatachalam R, et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011;32:407-14. [Crossref] [PubMed]
32. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009;48:737-44. [Crossref] [PubMed]
33. Goel A, Nguyen TP, Leung HC, et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer 2011;128:869-78. [Crossref] [PubMed]
34. Banchereau R, Chitre AS, Scherl A, et al. Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. J Immunother Cancer 2021;9:e002231. [Crossref] [PubMed]
35. Ichiki Y, Ueno M, Yanagi S, et al. An analysis of the immunological tumor microenvironment of primary tumors and regional lymph nodes in squamous cell lung cancer. Transl Lung Cancer Res 2021;10:3520-37. [Crossref] [PubMed]
36. Ichiki Y, Fukuyama T, Ueno M, et al. Immune profile analysis of peripheral blood and tumors of lung cancer patients treated with immune checkpoint inhibitors. Transl Lung Cancer Res 2022;11:2192-207. [Crossref] [PubMed]
37. Ichiki Y, Takenoyama M, Mizukami M, et al. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J Immunol 2004;172:4844-50. [Crossref] [PubMed]
38. Ichiki Y, Shigematsu Y, Baba T, et al. Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells. Cancer Sci 2020;111:4021-30. [Crossref] [PubMed]
39. Kagamu H, Kitano S, Yamaguchi O, et al. CD4(+) T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy. Cancer Immunol Res 2020;8:334-44. [Crossref] [PubMed]
40. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science 2013;339:286-91. [Crossref] [PubMed]
41. Speiser DE, Utzschneider DT, Oberle SG, et al. T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? Nat Rev Immunol 2014;14:768-74. [Crossref] [PubMed]
42. Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306. [Crossref] [PubMed]
43. Wouters MCA, Nelson BH. Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer. Clin Cancer Res 2018;24:6125-35. [Crossref] [PubMed]
44. Cipponi A, Mercier M, Seremet T, et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012;72:3997-4007. [Crossref] [PubMed]
45. Germain C, Gnjatic S, Dieu-Nosjean MC. Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Front Immunol 2015;6:67. [Crossref] [PubMed]
46. Li JP, Wu CY, Chen MY, et al. PD-1(+)CXCR5(-)CD4(+) Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. J Immunother Cancer 2021;9:e002101. [Crossref] [PubMed]
47. Xia J, Xie Z, Niu G, et al. Single-cell landscape and clinical outcomes of infiltrating B cells in colorectal cancer. Immunology 2023;168:135-51. [Crossref] [PubMed]
48. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61. [Crossref] [PubMed]
49. Turner JA, Stephen-Victor E, Wang S, et al. Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity. Immunity 2020;53:1202-1214.e6. [Crossref] [PubMed]
50. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007;13:108-16. [Crossref] [PubMed]
51. Nagai H, Horikawa T, Hara I, et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer. Exp Dermatol 2004;13:613-20. [Crossref] [PubMed]
52. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115:3623-33. [Crossref] [PubMed]
53. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-5. [Crossref] [PubMed]
54. Wang L, Simons DL, Lu X, et al. Connecting blood and intratumoral Treg cell activity in predicting future relapse in breast cancer. Nat Immunol 2019;20:1220-30. [Crossref] [PubMed]
55. Wing JB, Tanaka A, Sakaguchi S. Human FOXP3(+) Regulatory T Cell Heterogeneity and Function in Autoimmunity and Cancer. Immunity 2019;50:302-16. [Crossref] [PubMed]
56. Kanamori M, Nakatsukasa H, Okada M, et al. Induced Regulatory T Cells: Their Development, Stability, and Applications. Trends Immunol 2016;37:803-11. [Crossref] [PubMed]
57. Leonard JD, Gilmore DC, Dileepan T, et al. Identification of Natural Regulatory T Cell Epitopes Reveals Convergence on a Dominant Autoantigen. Immunity 2017;47:107-117.e8. [Crossref] [PubMed]
58. Downs-Canner S, Berkey S, Delgoffe GM, et al. Suppressive IL-17A+Foxp3+ and ex-Th17 IL-17AnegFoxp3+ Treg cells are a source of tumour-associated Treg cells. Nat Commun 2017;8:14649. [Crossref] [PubMed]
59. Watson MJ, Vignali PDA, Mullett SJ, et al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature 2021;591:645-51. [Crossref] [PubMed]
60. Gerriets VA, Kishton RJ, Johnson MO, et al. Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression. Nat Immunol 2016;17:1459-66. [Crossref] [PubMed]
61. Smyth MJ, Hayakawa Y, Takeda K, et al. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61. [Crossref] [PubMed]
62. Campos-Martín Y, Gómez del Moral M, Gozalbo-López B, Suela J, Martínez-Naves E. Expression of human CD1d molecules protects target cells from NK cell-mediated cytolysis. J Immunol. 2004;172:7297-305. [Crossref] [PubMed]
63. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-9. [Crossref] [PubMed]
64. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005;65:6321-9. [Crossref] [PubMed]
65. Skov S, Pedersen MT, Andresen L, et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005;65:11136-45. [Crossref] [PubMed]
66. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005. [Crossref] [PubMed]
67. Moretta L, Bottino C, Pende D, et al. Different checkpoints in human NK-cell activation. Trends Immunol 2004;25:670-6. [Crossref] [PubMed]
68. Baba T, Hanagiri T, Ichiki Y, et al. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci 2007;98:1795-802. [Crossref] [PubMed]
69. Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov 2020;19:200-18. [Crossref] [PubMed]
70. Godfrey DI, Le Nours J, Andrews DM, et al. Unconventional T Cell Targets for Cancer Immunotherapy. Immunity 2018;48:453-73. [Crossref] [PubMed]
71. Fujii S, Shimizu K, Kronenberg M, et al. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat Immunol 2002;3:867-74. [Crossref] [PubMed]
72. Fujii S, Shimizu K, Smith C, et al. Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003;198:267-79. [Crossref] [PubMed]
73. Shimizu K, Kurosawa Y, Taniguchi M, et al. Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells. J Exp Med 2007;204:2641-53. [Crossref] [PubMed]
74. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 2009;31:184-96. [Crossref] [PubMed]
75. Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37:1191-7. [Crossref] [PubMed]
76. Sakamoto M, Nakajima J, Murakawa T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study. J Immunother 2011;34:202-11. [Crossref] [PubMed]
77. Leonardi I, Gao IH, Lin WY, et al. Mucosal fungi promote gut barrier function and social behavior via Type 17 immunity. Cell 2022;185:831-846.e14. [Crossref] [PubMed]
78. Gaffen SL, Moutsopoulos NM. Regulation of host-microbe interactions at oral mucosal barriers by type 17 immunity. Sci Immunol 2020;5:eaau4594. [Crossref] [PubMed]
79. Li X, Bechara R, Zhao J, McGeachy MJ, et al. IL-17 receptor-based signaling and implications for disease. Nat Immunol 2019;20:1594-602. [Crossref] [PubMed]
80. Jin C, Lagoudas GK, Zhao C, et al. Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell 2019;176:998-1013.e16. [Crossref] [PubMed]
81. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014;41:49-61. [Crossref] [PubMed]
82. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010;22:231-7. [Crossref] [PubMed]
83. Deng S, Wang J, Hu Y, et al. Irradiated tumour cell-derived microparticles upregulate MHC-I expression in cancer cells via DNA double-strand break repair pathway. Cancer Lett 2024;592:216898. [Crossref] [PubMed]
84. Wan C, Sun Y, Tian Y, et al. Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. Sci Adv 2020;6:eaay9789. [Crossref] [PubMed]
85. Goc J, Germain C, Vo-Bourgais TK, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res 2014;74:705-15. [Crossref] [PubMed]
86. Dutertre CA, Wang LF, Ginhoux F. Aligning bona fide dendritic cell populations across species. Cell Immunol 2014;291:3-10. [Crossref] [PubMed]
87. Haniffa M, Collin M, Ginhoux F. Ontogeny and functional specialization of dendritic cells in human and mouse. Adv Immunol 2013;120:1-49. [Crossref] [PubMed]
88. Lavin Y, Kobayashi S, Leader A, et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell 2017;169:750-765.e17. [Crossref] [PubMed]
89. Van den Bossche J, De Laere M, Deschepper K, et al. Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma-Protocol of the Immuno-MESODEC study. PLoS One 2024;19:e0307204. [Crossref] [PubMed]
90. van ‘t Land FR, Willemsen M, Bezemer K, et al. Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer. J Clin Oncol 2024;42:3083-93. [Crossref] [PubMed]
91. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol 2018;19:108-19. [Crossref] [PubMed]
92. Hengesbach LM, Hoag KA. Physiological concentrations of retinoic acid favor myeloid dendritic cell development over granulocyte development in cultures of bone marrow cells from mice. J Nutr 2004;134:2653-9. [Crossref] [PubMed]
93. Nefedova Y, Nagaraj S, Rosenbauer A, et al. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005;65:9525-35. [Crossref] [PubMed]
94. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005;11:1314-21. [Crossref] [PubMed]
95. Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 2005;11:6713-21. [Crossref] [PubMed]
96. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99-108. [Crossref] [PubMed]
97. Aruga A, Aruga E, Cameron MJ, et al. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. J Leukoc Biol 1997;61:507-16. [Crossref] [PubMed]
98. Uribe-Querol E, Rosales C. Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res 2015;2015:983698. [Crossref] [PubMed]
99. Canli Ö, Nicolas AM, Gupta J, et al. Myeloid Cell-Derived Reactive Oxygen Species Induce Epithelial Mutagenesis. Cancer Cell 2017;32:869-883.e5. [Crossref] [PubMed]
100. Houghton AM, Rzymkiewicz DM, Ji H, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med 2010;16:219-23. [Crossref] [PubMed]
101. Nozawa H, Chiu C, Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc Natl Acad Sci U S A 2006;103:12493-8. [Crossref] [PubMed]
102. Kaltenmeier C, Simmons RL, Tohme S, et al. Neutrophil Extracellular Traps (NETs) in Cancer Metastasis. Cancers (Basel) 2021;13:6131. [Crossref] [PubMed]
103. Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Lung Cancer 2017;111:176-81. [Crossref] [PubMed]
104. Tanizaki J, Haratani K, Hayashi H, et al. Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Thorac Oncol 2018;13:97-105. [Crossref] [PubMed]
105. Ilie M, Hofman V, Ortholan C, et al. Predictive clinical outcome of the intratumoral CD66b-positive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer 2012;118:1726-37. [Crossref] [PubMed]
106. Panciera T, Azzolin L, Cordenonsi M, et al. Mechanobiology of YAP and TAZ in physiology and disease. Nat Rev Mol Cell Biol 2017;18:758-70. [Crossref] [PubMed]
107. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015;16:225-38. [Crossref] [PubMed]
108. Vermeulen L, De Sousa E, Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-76. [Crossref] [PubMed]
109. Calvo F, Ege N, Grande-Garcia A, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013;15:637-46. [Crossref] [PubMed]
110. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-54. [Crossref] [PubMed]
111. Cords L, Engler S, Haberecker M, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell 2024;42:396-412.e5. [Crossref] [PubMed]
112. Tan E, Gakhar N, Kirtane K. TCR gene-engineered cell therapy for solid tumors. Best Pract Res Clin Haematol 2021;34:101285. [Crossref] [PubMed]
113. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 2021;11:69. [Crossref] [PubMed]
114. Zhong S, Cui Y, Liu Q, et al. CAR-T cell therapy for lung cancer: a promising but challenging future. J Thorac Dis 2020;12:4516-21. [Crossref] [PubMed]
115. Liang T, Wang B, Li J, et al. LINC00922 Accelerates the Proliferation, Migration and Invasion of Lung Cancer Via the miRNA-204/CXCR4 Axis. Med Sci Monit 2019;25:5075-86. [Crossref] [PubMed]
116. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biol Ther 2010;9:409-16. [Crossref] [PubMed]
117. Mao Y, Fan W, Hu H, et al. MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. J Hematol Oncol 2019;12:106. [Crossref] [PubMed]
118. Kinoshita S, Ishii M, Ando J, et al. Rejuvenated iPSC-derived GD2-directed CART Cells Harbor Robust Cytotoxicity Against Small Cell Lung Cancer. Cancer Res Commun 2024;4:723-37. [Crossref] [PubMed]
119. Moles MW, Erdlei H, Menzel L, et al. CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma. Front Immunol 2024;15:1383136. [Crossref] [PubMed]
120. Li W, Qiu S, Chen J, et al. Chimeric Antigen Receptor Designed to Prevent Ubiquitination and Downregulation Showed Durable Antitumor Efficacy. Immunity 2020;53:456-470.e6. [Crossref] [PubMed]
121. Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. N Engl J Med 2022;386:2112-9. [Crossref] [PubMed]
122. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29:917-24. [Crossref] [PubMed]